Share on StockTwits

Theravance (NASDAQ:THRX) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 20,325,846 shares, a growth of 16.3% from the April 30th total of 17,477,346 shares, AR Network reports. Based on an average trading volume of 1,037,825 shares, the days-to-cover ratio is presently 19.6 days. Currently, 25.9% of the company’s stock are sold short.

A number of research firms have recently commented on THRX. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Theravance in a research note on Wednesday, May 7th. They now have a $47.00 price target on the stock, down previously from $52.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note on Wednesday, May 7th. They now have a $29.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note on Thursday, April 24th. They now have a $28.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $31.90.

Theravance (NASDAQ:THRX) opened at 28.65 on Monday. Theravance has a 52 week low of $25.11 and a 52 week high of $42.96. The stock has a 50-day moving average of $27.38 and a 200-day moving average of $33.60. The company’s market cap is $3.227 billion.

Theravance (NASDAQ:THRX) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter in the previous year, the company posted ($0.39) earnings per share. The company’s revenue for the quarter was down 87.3% on a year-over-year basis. On average, analysts predict that Theravance will post $-1.81 earnings per share for the current fiscal year.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.